With 1.23 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.42 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $67.31 whereas the lowest price it dropped to was $63.81. The 52-week range on VRNA shows that it touched its highest point at $70.40 and its lowest point at $11.39 during that stretch. It currently has a 1-year price target of $80.33. Beta for the stock currently stands at 0.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VRNA was up-trending over the past week, with a rise of 0.33%, but this was down by -1.74% over a month. Three-month performance surged to 66.70% while six-month performance rose 127.14%. The stock gained 319.21% in the past year, while it has gained 43.80% so far this year. A look at the trailing 12-month EPS for VRNA yields -2.16 with Next year EPS estimates of 0.51. For the next quarter, that number is -0.07. This implies an EPS growth rate of 128.70% for this year and 558.06% for next year.
Float and Shares Shorts:
At present, 84.63 million VRNA shares are outstanding with a float of 74.21 million shares on hand for trading. On 2025-02-28, short shares totaled 9.0 million, which was 1059.00005 higher than short shares on 1738281600. In addition to Dr. David S. Zaccardelli Pharm.D. as the firm’s President, CEO & Executive Director, Mr. Mark W. Hahn serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, VRNA reported revenue of $36655000.0 and operating income of -$17783000.0. The EBITDA in the recently reported quarter was -$13530000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VRNA since 7 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VRNA analysts setting a high price target of 93.0 and a low target of 72.0, the average target price over the next 12 months is 81.0. Based on these targets, VRNA could surge 39.26% to reach the target high and rise by 7.82% to reach the target low. Reaching the average price target will result in a growth of 21.29% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.43432 being high and -$0.50985 being low. For VRNA, this leads to a yearly average estimate of -$0.46028. Based on analyst estimates, the high estimate for the next quarter is -$0.01 and the low estimate is -$0.03. The average estimate for the next quarter is thus -$0.02.
